Experience with BCG Adjuvant Immunotherapy in Stage II Malignant Melanoma
Open Access
- 1 May 1977
- journal article
- research article
- Published by SAGE Publications in Tumori Journal
- Vol. 63 (3) , 303-307
- https://doi.org/10.1177/030089167706300309
Abstract
Three years experience with post operative BCG adjuvant immunotherapy in stage II malignant melanoma is reported. Compared to a historical control group (35 cases), 23 melanoma patients showed a significantly improved remission duration and survival rate. It appears that patients with weak initial BCG reactions, which become gradually positive after several immunizations, get more benefit from the adjuvant immunotherapy than do patients with strongly positive initial BCG reactions.This publication has 4 references indexed in Scilit:
- Adjuvant Immunotherapy with BCG in Treatment of Regional-Lymph-Node Metastases from Malignant MelanomaNew England Journal of Medicine, 1976
- Immunotherapy in the Management of LeukaemiaBritish Journal of Haematology, 1975
- RESULTS OF ADMINISTERING B.C.G. TO PATIENTS WITH MELANOMAThe Lancet, 1974
- Immunological Effects of BCG in Malignant Melanoma: Two Modes of Administration ComparedAnnals of Internal Medicine, 1972